Kidney stone DNA and tissue sample biobank study
Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study collects and stores donated samples (like blood, urine, and tissue) from people with certain rare inherited kidney stone conditions. The goal is to build a resource for future research that could help improve diagnosis and treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these rare conditions: primary hyperoxaluria, Dent disease, APRT deficiency (dihydroxyadeninuria), or cystinuria
- You’re able to provide samples and give consent (or have already given consent for sample banking)
- Your condition is confirmed by genetic testing, urine/stone results, or doctor/lab findings
- If you don’t have liver biopsy or genetic results (end-stage kidney failure), you must have specific blood/biopsy or whole-body oxalate evidence
- Or you are a close relative of someone with one of the listed confirmed conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry collects information from people with certain inherited rare kidney stone conditions. It helps researchers learn about the conditions and supports future studies that may improve care.
This study is for people with certain rare kidney conditions that can cause kidney stones. It aims to learn how these conditions behave over time and may help improve future care.
This study uses genetic testing to look for inherited (“monogenic”) reasons some people get kidney stones. It may help explain the cause of stones and calcium-related problems, which can guide future care for you or your family.
This trial tests a new treatment called ABO-101 for people with primary hyperoxaluria type 1, a rare disease that causes high oxalate levels in urine. The study aims to see if ABO-101 can lower oxalate and protect kidney function.
This study tests a new treatment for primary hyperoxaluria type 1, a rare condition that causes too much oxalate in the body, which can lead to kidney stones and kidney damage. The treatment is given as an injection, and the study will see if it is safe and how the body responds.
This Phase 2 study tests a medicine called DCR-PHXC to lower body oxalate levels in people with PH1 who have advanced kidney failure. By lowering oxalate, the treatment may reduce harm from oxalate buildup and help researchers understand safety and effectiveness.
Hear when a new Primary Hyperoxaluria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.